克里唑替尼治疗晚期非小细胞肺癌的临床研究进展

At present, in the treatment of non-small cell lung cancer (NSCLC), targeted therapy has an important status. After epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKIs), crizotinib targeted at EML4-ALK fusion gene becomes a significant drug of molecular targeted therapy in NSCLC. P...

Full description

Saved in:
Bibliographic Details
Published in:Zhongguo Fei Ai Za Zhi
Format: Artigo
Language:Inglês
Published: 中国肺癌杂志编辑部 2013
Subjects:
综述
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC6000565/
https://ncbi.nlm.nih.gov/pubmed/23769348
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3779/j.issn.1009-3419.2013.06.09
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items